Kevin P. Malobisky
Chief Operating Officer at DBV TECHNOLOGIES
Kevin P. Malobisky active positions
Companies | Position | Start | End |
---|---|---|---|
DBV TECHNOLOGIES | Chief Operating Officer | 30/11/2023 | - |
Career history of Kevin P. Malobisky
Former positions of Kevin P. Malobisky
Companies | Position | Start | End |
---|---|---|---|
ACHILLION PHARMACEUTICALS, INC. | Compliance Officer | 31/12/2017 | 27/01/2020 |
General Counsel | 31/12/2017 | 27/01/2020 | |
KARYOPHARM THERAPEUTICS INC. | General Counsel | 31/10/2016 | 31/08/2018 |
LARIMAR THERAPEUTICS, INC. | General Counsel | 26/05/2015 | 31/07/2016 |
Tavanta Therapeutics, Inc.
Tavanta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tavanta Therapeutics, Inc. operates as a clinical-stage pharmaceutical company developing a diverse pipeline of specialty drugs. The company is based in King of Prussia, PA and has subsidiaries in Hungary. Lynne M. Powell has been the CEO of the company since 2019. | Corporate Officer/Principal | - | - |
Revelar Biotherapeutics, Inc.
Revelar Biotherapeutics, Inc. BiotechnologyHealth Technology Revelar Biotherapeutics is a biopharmaceutical company based in Bethesda, MD. Revelar Biotherapeutics, Inc. focuses on developing and commercializing breakthrough therapeutic antibody products to address critical unmet patient needs, particularly in the field of COVID-19 and other therapeutic areas. The company's management team has extensive expertise in clinical development, regulatory affairs, business development, and operations with leading pharmaceutical companies. Revelar was spun out of Twist Bioscience in November 2021 and has the ability to leverage Twist Biopharma's antibody discovery and optimization platform to license additional antibodies for non-COVID targets. The company's therapeutic areas of interest include oncology and infectious diseases. Revelar aims to combine its clinical development and commercialization capabilities with Twist's innovative technology platform and industry and academia collaborations to accelerate the discovery and delivery of transformative antibody therapeutics to meet patients' unmet needs. Revelar was founded by Kevin P. Malobisky, and the CEO is Glenn Marina. | Founder | - | - |
Corporate Officer/Principal | - | - |
Training of Kevin P. Malobisky
Temple University School of Pharmacy | Graduate Degree |
Capella University LLC | Doctorate Degree |
The Pennsylvania State University | Undergraduate Degree |
Statistics
International
United States | 9 |
France | 2 |
Operational
General Counsel | 3 |
Corporate Officer/Principal | 2 |
Graduate Degree | 1 |
Sectoral
Health Technology | 7 |
Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
KARYOPHARM THERAPEUTICS INC. | Health Technology |
DBV TECHNOLOGIES | Health Technology |
Private companies | 4 |
---|---|
Zafgen, Inc.
Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Revelar Biotherapeutics, Inc.
Revelar Biotherapeutics, Inc. BiotechnologyHealth Technology Revelar Biotherapeutics is a biopharmaceutical company based in Bethesda, MD. Revelar Biotherapeutics, Inc. focuses on developing and commercializing breakthrough therapeutic antibody products to address critical unmet patient needs, particularly in the field of COVID-19 and other therapeutic areas. The company's management team has extensive expertise in clinical development, regulatory affairs, business development, and operations with leading pharmaceutical companies. Revelar was spun out of Twist Bioscience in November 2021 and has the ability to leverage Twist Biopharma's antibody discovery and optimization platform to license additional antibodies for non-COVID targets. The company's therapeutic areas of interest include oncology and infectious diseases. Revelar aims to combine its clinical development and commercialization capabilities with Twist's innovative technology platform and industry and academia collaborations to accelerate the discovery and delivery of transformative antibody therapeutics to meet patients' unmet needs. Revelar was founded by Kevin P. Malobisky, and the CEO is Glenn Marina. | Health Technology |
Tavanta Therapeutics, Inc.
Tavanta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tavanta Therapeutics, Inc. operates as a clinical-stage pharmaceutical company developing a diverse pipeline of specialty drugs. The company is based in King of Prussia, PA and has subsidiaries in Hungary. Lynne M. Powell has been the CEO of the company since 2019. | Health Technology |
- Stock Market
- Insiders
- Kevin P. Malobisky
- Experience